1. PI3K/Akt/mTOR
  2. PDK-1

BX-912 

Cat. No.: HY-11005 Purity: 98.94%
Handling Instructions

BX-912 is a potent PDK1 inhibitors with an IC50 of 12 nM.

For research use only. We do not sell to patients.
BX-912 Chemical Structure

BX-912 Chemical Structure

CAS No. : 702674-56-4

Size Price Stock Quantity
10 mM * 1 mL in DMSO USD 178 In-stock
5 mg USD 162 In-stock
50 mg USD 648 In-stock
100 mg USD 972 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

Featured Recommendations

Related Small Molecules:

  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

  • References

Description

BX-912 is a potent PDK1 inhibitors with an IC50 of 12 nM.

IC50 & Target

IC50: 12 nM (PDK1), 110 nM (PKA), 410 nM (KDR), 650 nM (CDK2/cyclin E), 830 nM (Chck1), 850 nM (c-Kit), 1.25 μM (PKC), 2.1 μM (T-Fyn), 6.1 μM (Insulin receptor), 7.4 μM (GSK3β)[1]

In Vitro

BX-912 also inhibits PKA, KDR, CDK2/cyclin E, Chck1, c-Kit, PKC, T-Fyn, Insulin receptor, and GSK3β with IC50s of 110 nM, 410 nM, 650 nM, 830 nM, 850 nM, 1.25 μM, 2.1 μM, 6.1 μM and 7.4 μM in kinase assays, respectively. BX-912 is identified in a coupled assay measuring PDK1- and PtdIns-3,4-P2-mediated Akt activation, which can detect inhibitors of PDK1, AKT2, or other steps critical for activation of AKT2. BX-912 potently inhibits PDK1 enzyme activity in a direct kinase assay format (IC50=26), although BX-912 fails to block preactivated AKT2 activity (IC50>10 μM). BX-912 binds to the ATP binding site of PDK1. The aminopyrimidine backbone of BX-912 adopts a similar orientation in the active site of PDK1. To examine the kinase selectivity of BX-912, its effects on the in vitro activity of 10 different Ser/Thr and tyrosine kinases are determined, including the related AGC kinases PKA and PKCα. BX-912 is 9-fold selective for PDK1 relative to PKA. BX-912 blocks PDK1 activity in PTEN-negative PC-3 cells. PTEN-negative PC-3 cells display constitutive activation of Akt which is reflected in high levels of the PDK1 product, phospho-Thr308-Akt[1].

References
Preparing Stock Solutions
Concentration Volume Mass 1 mg 5 mg 10 mg
1 mM 2.1216 mL 10.6078 mL 21.2157 mL
5 mM 0.4243 mL 2.1216 mL 4.2431 mL
10 mM 0.2122 mL 1.0608 mL 2.1216 mL
Please refer to the solubility information to select the appropriate solvent.
Kinase Assay
[1]

PDK1 is assayed in a direct kinase assay and a coupled assay format measuring PDK1 and PtdIns-3,4-P2 mediated activation of AKT2. For the coupled assay, the final assay mixture (60 μL) contains: 15 mM MOPS, pH 7.2, 1 mg/mL bovine serum albumin, 18 mM β-glycerol phosphate, 0.7 mM dithiothreitol, 3 mM EGTA, 10 mM MgOAc, 7.5 μM ATP, 0.2 μCi of [γ-33P]ATP, 7.5 μM biotinylated peptide substrate (biotin-ARRRDGGGAQPFRPRAATF), 0.5 μL of PtdIns-3,4-P2-containing phospholipid vesicles, 60 pg of purified recombinant human PDK1, and 172 ng of purified recombinant human AKT2. After incubation for 2 h at room temperature, the biotin-labeled peptide is captured from 10 μL of the assay mixture on Streptavidin-coated SPA beads, and product formation is measured by scintillation proximity in a Wallac MicroBeta counter. The product formed is proportional to the time of incubation and to the amount of PDK1 and inactive AKT2 added. PDK1 is added at suboptimal levels so that the assay can sensitively detect inhibitors of AKT2 activation as well as direct inhibitors of PDK1 or AKT2[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Assay
[1]

BX-912 is dissolved in DMSO and then diluted with growth medium (final concentration of DMSO, 0.1%)[1].

The cell lines MDA-468, MDA-453, HCT-116, U87-MG, U2OS, PC-3, B16F10, and MiaPaCa; LOX amelanotic human melanoma cells; and HeLa cells seeded at a low density (1,500-3,000 cells/well, 0.1 mL/well, 96-well plates) are incubated overnight. Compound treatments are made by adding 10 μL/well of BX-912 (1, 10, 100 and 1000 nM) in 1% DMSO and growth medium (final concentration of DMSO, 0.1%), followed by brief shaking. Treated cells are incubated for 72 h, and viability is measured by the addition of 10 μL of the metabolic dye WST-1. The WST-1 signal is read in a plate reader at 450 nm, and a no cell, or zero time cell, background is subtracted to calculate the net signal[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

References
Molecular Weight

471.35

Formula

C₂₀H₂₃BrN₈O

CAS No.

702674-56-4

SMILES

BrC1=C(NCCC2=CNC=N2)N=C(NC3=CC(NC(N4CCCC4)=O)=CC=C3)N=C1

Storage
Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
Shipping

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

DMSO

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number *

 

Organization name *

Country *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
BX-912
Cat. No.:
HY-11005
Quantity: